A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old
Latest Information Update: 09 Jun 2026
At a glance
- Drugs Tenapanor (Primary)
- Indications Constipation; Irritable bowel syndrome
- Focus Registrational; Therapeutic Use
- Acronyms R-Ally
- Sponsors Ardelyx
Most Recent Events
- 04 Jun 2026 Planned End Date changed from 1 Jun 2026 to 1 Sep 2026.
- 04 Jun 2026 Planned primary completion date changed from 1 Jun 2026 to 1 Sep 2026.
- 04 Jun 2026 Status changed from recruiting to active, no longer recruiting.